检索结果-南通市图书馆

Effect and safety of anaprazole in the treatment of duodenal ulcers:a randomized,rabeprazole-controlled,phase Ⅲ non-inferiority study

引用

Chinese Medical Journal 2022年第24期135卷 2941-2949页

作者： Huiyun Zhu Xue Pan Li Zhang Hongxin Sun Huizhen Fan Zhongwei Pan Caibin Huang Zhenwang Shi Jin Ding Qi Wang Yiqi Du nonghua Lyu Zhaoshen Li Department of Gastroenterology Changhai Hospital of Navy Military Medical UniversityShanghai 200433China Drug Clinical trial Institution Changhai Hospital of Navy Military Medical UniversityShanghai 200433China Department of Gastroenterology Yichun People’s HospitalYichunJiangxi 336028China Department of Gastroenterology Meihekou Central HospitalMeihekouJilin 135099China Department of Gastroenterology The First Affiliated Hospital of Gannan Medical CollegeGanzhouJiangxi 341001China Department of Gastroenterology Hefei Second People’s HospitalHefeiAnhui 230011China Department of Gastroenterology Jinhua Central HospitalJinhuaZhejiang 321099China Department of Gastroenterology Anqing Municipal HospitalAnqingAnhui 246004China Department of Gastroenterology The First Affiliated Hospital of Nanchang UniversityNanchangJiangxi 330006China

Background:The pharmacokinetic and clinical behaviors of many proton pump inhibitors(PPIs)in peptic ulcer treatment are altered by CYP2C19 genetic *** non-inferiority study evaluated the efficacy and safety of the novel PPI anaprazole compared with *** also explored the influence of Helicobacter pylori(***)infection status and CYP2C19 polymorphism on ***:In this multicenter,randomized,double-blind,double-dummy,positive-drug parallel-controlled,phase Ⅲ study,Chinese patients with duodenal ulcers were randomized 1:1 to receive rabeprazole 10 mg+anaprazole placebo or rabeprazole placebo+anaprazole 20 mg once daily for 4 *** primary efficacy endpoint was the 4-week ulcer healing rate assessed by blinded independent *** endpoints were the proportion of patients with improved overall and individual duodenal ulcer symptoms at 4 ***,exploratory subgroup analysis of the primary endpoint by *** status and CYP2C19 polymorphism was *** events were monitored for ***-inferiority analysis was conducted for the primary ***:The study enrolled 448 patients(anaprazole,n=225;rabeprazole,n=223).The 4-week healing rates were 90.9%and 93.7%for anaprazole and rabeprazole,respectively(difference,-2.8%[95%confidence interval,-7.7%,2.2%]),demonstrating non-inferiority of anaprazole to *** duodenal ulcer symptoms improved in 90.9%and 92.5%of patients,*** rates of individual symptoms were similar between the *** rates did not significantly differ by *** status or CYP2C19 genotype for either treatment *** incidence of treatment-emergent adverse events was similar for anaprazole(72/220,32.7%)and rabeprazole(84/219,38.4%).Conclusions:The efficacy of anaprazole is non-inferior to that of rabeprazole in Chinese patients with duodenal ***:***,NCT04215653.

关键词： Cytochrome P-450 CYP2C19 non-inferiority trial Peptic ulcer Polymorphism Genetic Proton pump inhibitors Anaprazole Rabeprazole

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：